Abstract:AbstractBackgroundAmong the indicated pathogenic factors of Alzheimer’s disease (AD), mitochondrial dysfunction has been recognized as an essential contributor, especially for the late onset AD (LOAD). That this observed dysfunction is the cause or consequences of other AD‐related injuries has been debated, results from both sides are in agreement that the roles of mitochondria in connection with other AD pathologies are convergent. This strongly advocates that targeting mitochondrial dysfunction represents a promising approach to develop more effective AD therapeutics.MethodChemical probes based on a novel lead structure that showed promising neuroprotective activities both in vitro and in vivo AD models were designed and synthesized to identify protein targets. Mouse brain mitochondria were purified from C57BL/6 mice and complex I was further isolated. OXPHOS studies were conducted in purified mitochondria upon treatment with our lead compound. Photo‐affinity labeling studies were conducted upon incubation of chemical probes with complex I. Colocalization was studied using neuronal MC65 cells and chemical probes.ResultOXPHOS studies established that the lead compound only modulated the state 3 respiratory of pyruvate, the complex I substrate, but not succinate, the complex II substrate. Enzymatic studies of ETC also confirmed its selective modulation of complex I. The immunocytochemistry studies in MC65 cells indicated that the designed chemical probe localized to mitochondria. Protein labeling studies confirmed the direct interaction of the chemical probe with mitochondria complex I. Further analysis suggested that our chemical probe binds to the FMN binding site of complex I. Competition studies using the lead compound and NADH supported the selective labeling of complex I sub‐units.ConclusionStudies from in vitro, ex vivo, and in vivo models established that the lead compound selectively modulates the production of mitochondria complex I ROS without interfering with mitochondria membrane potential and bioenergetics, representing a novel mechanism of action. Chemical biology studies employing photo‐affinity labeling probes also confirmed the interaction of the probes with complex I and suggested the FMN binding site as the interaction site. Collectively, the results strongly encourage developing mitochondria complex I ROS modulators based on this novel chemical scaffold as potential AD therapeutics.

Tracking Mitochondrial Cu(I) Fluctuations Through a Ratiometric Fluorescent Probe in AD Model Cells: Towards Understanding How AβOs Induce Mitochondrial Cu(I) Dyshomeostasis

Changes In Mitochondrial Dynamics During Amyloid Beta-Induced Pc12 Cell Apoptosis

Targeting Zincosomes to Unveil Lysosomal Zinc ion Dynamics and Their Role in Exacerbating Alzheimer's Pathology

Electrochemical Strategy for Analyzing the Co-evolution of Cu2+ and •OH Levels at the Early Stages of Transgenic AD Mice

A Quinolinium-Based Dual-Functional NIR Fluorescent Probe for the Imaging of Aβ Aggregation and Mitochondrial Ph

Two-photon and Dual-Color Visualization of Aβ1-40 Induced Mitophagy by the Detection of Mitochondrial DNA G-quadruplex and Polarity

Novel Modulators of Mitochondrial Complex I ROS Production As Potential AD Therapeutics

Sensitive Imaging and Effective Capture of Cu2+: Towards Highly Efficient Theranostics of Alzheimer's Disease

The Double-Edged Role of Copper in the Fate of Amyloid Beta in the Presence of Anti-Oxidants.

A Two-Photon Fluorescent Probe Sensitive to NADPH Reveals Metabolic Aberrations in Brain Cells Arising from Mitochondrial Dysfunction in Alzheimer’s Disease

A coumarin-based multifunctional chemosensor for Cu 2+ /Al 3+ as an AD theranostic agent: Synthesis, X-ray single crystal analysis and activity study

Versatile Fluorescence Lifetime-Based Copper Probe to Quantify Mitochondrial Membrane Potential and Reveal Its Interaction with Protein Aggregation.

Mitochondria-targeting Cu2-xSe-TPP with dual enzyme activity alleviates Alzheimer's disease by modulating oxidative stress

Mitochondrial Toxic Effects of Aβ Through Mitofusins in the Early Pathogenesis of Alzheimer’s Disease

Dual-Channel Imaging of Amyloid-β Plaques and Peroxynitrite to Illuminate Their Correlations in Alzheimer’s Disease Using a Unimolecular Two-Photon Fluorescent Probe

An Activity-Based Sensing Fluorescent Probe for Monitoring Endogenous Peroxynitrite in Alzheimer's Disease Models

A Single Biosensor for Evaluating the Levels of Copper Ion and L-Cysteine in a Live Rat Brain with Alzheimer's Disease.

Altered Copper Transport in Oxidative Stress-Dependent Brain Endothelial Barrier Dysfunction Associated with Alzheimer′s Disease

Visualization of the elevated levels of hypochlorous acid in Alzheimer's disease with a ruthenium(II) complex-based luminescence probe

N-methylbenzothiazolium based theranostics as fluorescence imaging and photo-oxidation agents for Amyloid-β

Rational construction and evaluation of a dual-functional near-infrared fluorescent probe for the imaging of Amyloid-β and mitochondrial viscosity